Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

NeuExcell Starts Trial of Gene Therapy to Create Neurons for Glioblastoma

publication date: Mar 22, 2024

Suzhou NeuExcell Therapeutics, a company focused on in vivo neural regenerative therapies, dosed the first patient with a first-in-class NeuroD1 gene therapy product NXL-004. The company explains that neural tissues contain two major types of cells: neurons and supportive glial cells such as astrocytes. Although neurons cannot divide or replenish themselves, glial cells can.  Because both are derived from neural stem cells, neurons and astrocytes have many similar traits. NeuExcell applies its astrocyte-to-neuron (AtN) conversion technology to replace dead neurons in diseased or injured tissues. The investigator trial will evaluate NXL-004 in patients with glioblastoma. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital